Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.
about
Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratificationPopulation pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs.Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli.Pharmacodynamics of antimicrobials: treatment optimisation.Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists.The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?Pharmacokinetic and pharmacodynamic properties of meropenem.Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study.Pharmacological rationale for antibiotic treatment of intra-abdominal infections.Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review.Antibiotic dosing in critically ill patients with acute kidney injury.Carbapenem susceptibility breakpoints, clinical implications with the moving target.Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function.Optimization of meropenem dosage in the critically ill population based on renal function.Cure of persistent, post-appendectomy Klebsiella pneumoniae septicaemia with continuous intravenous administration of meropenem.Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial inDosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.Using Monte Carlo simulation to determine optimal dosing regimen for cefetamet sodium for injection.Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.[Pharmacokinetics and pharmacodynamics of antibiotics in intensive care].
P2860
Q24615937-CD353423-4FBA-4A5E-A812-176C430ABD2AQ30316322-1874F830-8231-425A-96B6-7CFE7D9CBF08Q34916515-3F79305E-3DE1-40E9-B553-ECE79711C560Q36076101-8DEAF276-66CA-4285-912D-65E155E55EF7Q36095041-E26F06CD-7699-4E65-852B-C046EE96FE73Q36452576-BB95BCD7-1B8F-4668-892E-A790DF3B44C8Q36544935-FFFC9A6E-6502-4D13-A699-5570D80A4BD0Q36582692-0B4681DE-D605-44FC-BC8F-6F0C3D59F4BDQ37098999-9A15E928-716E-4D39-B69A-AF933BC8E68BQ37146405-7BA396A8-0051-4AD6-B977-5AC759208B6BQ37247125-C7DDC996-3C6D-4B98-8DE7-7E4A5AE3EAD6Q37364236-06E4D255-CE87-4AE2-92D5-5E5184559517Q37557851-756C6F6E-7CF2-461E-8755-FBBD4E4C4A19Q37685856-528A0571-6964-49DC-980B-E4E34D267251Q37846092-BB4A83ED-4021-476A-9809-E6EC1FD829E6Q38751264-EBA7CAF3-9BE5-4EEF-A874-F24884C4FCB7Q39103144-558DAB44-60E8-41D4-A038-2931F3BC9ADDQ39961839-FA76B7BB-D941-40AA-BA21-28A9007E0AF5Q40471337-951AA785-4AA8-4B58-81EC-0035A401F9D5Q41349399-F82F4C93-56FB-4C88-B09C-98F21D3BEAEFQ41681159-D470F1F7-FE7E-49A8-881D-02F5B230DE73Q41727504-5CEEF0B6-875F-414C-8E3D-0705790E5A77Q42656891-E2C96734-E8DD-4F69-9207-BA751F746ACAQ46034494-90E6C356-481C-40D3-BA42-2F16F232FCE4Q46921577-D906CECC-8EA1-4B91-A41D-546EFCEC432DQ51751807-AA2E0482-38F3-45BD-88CA-DC3EA5E34326
P2860
Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Evaluation by monte carlo simu ...... nfusion in healthy volunteers.
@ast
Evaluation by monte carlo simu ...... nfusion in healthy volunteers.
@en
type
label
Evaluation by monte carlo simu ...... nfusion in healthy volunteers.
@ast
Evaluation by monte carlo simu ...... nfusion in healthy volunteers.
@en
prefLabel
Evaluation by monte carlo simu ...... nfusion in healthy volunteers.
@ast
Evaluation by monte carlo simu ...... nfusion in healthy volunteers.
@en
P2093
P2860
P50
P1476
Evaluation by monte carlo simu ...... infusion in healthy volunteers
@en
P2093
Fritz Sörgel
George L Drusano
Kurt G Naber
Martina Kinzig-Schippers
Wolfgang A Krueger
P2860
P304
P356
10.1128/AAC.49.5.1881-1889.2005
P407
P577
2005-05-01T00:00:00Z